ADVOCACY
-
Gene therapy for hemophilia B one step closer: CSL Behring and pCPA agree on pricing
MONTREAL, October 7, 2025 – CSL Behring Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) have announced signing of a Letter of Intent that sets pricing...
-
Update on novel therapies for hemophilia A and B
MONTRÉAL, September 19, 2025 – No announcements have been made over the summer on progress in gaining access to two novel hemophilia therapies. Altuviiio for...
-
WFH mobilizes global community to achieve milestone revisions to WHO EML
While this does not affect Canada directly, it is a major step forward for the international community and acknowledges what Canada is already doing in...
-
Reimbursement of Altuviiio recommended, but…
MONTRÉAL, July 3, 2025 – In June, both Canada’s Drug Agency (CDA) and Quebec’s Institut national d’excellence en santé et en services sociaux (INESSS) released...
-
Your FEEDBACK matters to us!
The CHS is currently developing the next CHS Strategic Plan. We would appreciate your insights into how we can further our mission and enhance our...